Floatz logo

azd5863

Gastro-esophageal Junction Cancer

AstraZenecaPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

112 Active assets in the Gastro-esophageal Junction Cancer cohort.

Asset / SponsorPhaseRating
Irinotecan
AstraZeneca
Phase 3BBB
Cyclophosphamide
Beijing Biotech
Phase 3BB
FLUOROURACILUM
Alliance for Clinical Trials in Oncology
Phase 3BB
Pembrolizumab
Eikon Therapeutics
Phase 3BB
Capecitabine
I-Mab Biopharma US Limited
Phase 3BB

View all 50 →

Same molecule, other indications

azd5863 is also rated in:

esophageal adenocarcinomaDormant
CC
Indicative ·
43 / 100
View asset →
gastric cancerDormant
CC
Indicative ·
41 / 100
View asset →
pancreatic ductal adenocarcinomaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →